• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.

作者信息

Suto Keito, Takei Norio, Yokoyama Keito, Chiba Masahiro, Ishio Takashi, Maeda Michiyuki, Goto Hideki, Endo Tomoyuki, Teshima Takanori, Yang Yibin, Nakagawa Masao

机构信息

Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.

Institute for Animal Experimentation, Hokkaido University Faculty of Medicine, Sapporo, Japan.

出版信息

Leukemia. 2025 Jan;39(1):243-247. doi: 10.1038/s41375-024-02441-1. Epub 2024 Oct 21.

DOI:10.1038/s41375-024-02441-1
PMID:39433928
Abstract
摘要

相似文献

1
Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.全基因组CRISPR筛选确定MAD2L1BP和ANAPC15是CD30+外周T细胞淋巴瘤中对brentuximab vedotin敏感性的靶点。
Leukemia. 2025 Jan;39(1):243-247. doi: 10.1038/s41375-024-02441-1. Epub 2024 Oct 21.
2
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.本妥昔单抗维迪辛联合环磷酰胺、多柔比星、依托泊苷和泼尼松治疗 CD30 阳性外周 T 细胞淋巴瘤：一项多中心、单臂、2 期研究。
Lancet Haematol. 2024 Sep;11(9):e671-e681. doi: 10.1016/S2352-3026(24)00171-6. Epub 2024 Jul 24.
3
Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.抗 CD30 抗体药物偶联物治疗淋巴瘤：现有知识、尚存争议和未来展望。
Ann Hematol. 2023 Jan;102(1):13-29. doi: 10.1007/s00277-022-05054-9. Epub 2022 Dec 13.
4
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.本妥昔单抗维布妥昔单抗治疗霍奇金淋巴瘤或系统性间变大细胞淋巴瘤患者的安全性和有效性。
Ther Adv Hematol. 2012 Aug;3(4):209-25. doi: 10.1177/2040620712443076.
5
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
6
Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.在用维布妥昔单抗治疗的复发性皮肤CD30+淋巴样肿瘤中，通过免疫组织化学检测发现CD30表达存在可变缺失。
J Cutan Pathol. 2019 Nov;46(11):823-829. doi: 10.1111/cup.13545. Epub 2019 Aug 2.
7
Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemia.成功用 Brentuximab vedotin 治疗复发/难治性成人 T 细胞白血病。
Anticancer Drugs. 2020 Jun;31(5):536-539. doi: 10.1097/CAD.0000000000000895.
8
Brentuximab vedotin in systemic T-cell lymphoma.本妥昔单抗维达汀治疗系统性 T 细胞淋巴瘤。
Expert Opin Biol Ther. 2012 May;12(5):623-32. doi: 10.1517/14712598.2012.670216. Epub 2012 Mar 20.
9
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.非霍奇金淋巴瘤中 CD30 表达对 Brentuximab Vedotin 的反应。
Oncologist. 2022 Oct 1;27(10):864-873. doi: 10.1093/oncolo/oyac137.
10
Brentuximab vedotin in T-cell lymphoma.本妥昔单抗维达汀治疗 T 细胞淋巴瘤。
Expert Rev Hematol. 2019 Jan;12(1):5-19. doi: 10.1080/17474086.2019.1558399. Epub 2018 Dec 18.

引用本文的文献

1
Antibody-Drug Conjugates Targeting CD30 in T-Cell Lymphomas: Clinical Progression and Mechanism.靶向T细胞淋巴瘤中CD30的抗体药物偶联物：临床进展与机制
Cancers (Basel). 2025 Feb 2;17(3):496. doi: 10.3390/cancers17030496.

本文引用的文献

1
Principles and dynamics of spindle assembly checkpoint signalling.纺锤体组装检验点信号转导的原理与动力学。
Nat Rev Mol Cell Biol. 2023 Aug;24(8):543-559. doi: 10.1038/s41580-023-00593-z. Epub 2023 Mar 24.
2
Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.全基因组 CRISPR 筛选鉴定出外周 T 细胞淋巴瘤中 CD48 决定对 NK 细胞毒性的易感性。
Blood. 2022 Nov 3;140(18):1951-1963. doi: 10.1182/blood.2022015646.
3
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
ECHELON-2 试验：brentuximab vedotin 联合化疗治疗 CD30 阳性外周 T 细胞淋巴瘤的随机 III 期研究的 5 年结果。
Ann Oncol. 2022 Mar;33(3):288-298. doi: 10.1016/j.annonc.2021.12.002. Epub 2021 Dec 16.
4
Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia/lymphoma.全基因组 CRISPR 筛选鉴定 CDK6 为成人 T 细胞白血病/淋巴瘤的治疗靶点。
Blood. 2022 Mar 10;139(10):1541-1556. doi: 10.1182/blood.2021012734.
5
Mitotic slippage is determined by p31 and the weakening of the spindle-assembly checkpoint.有丝分裂滑走取决于 p31 和纺锤体装配检查点的弱化。
Oncogene. 2020 Mar;39(13):2819-2834. doi: 10.1038/s41388-020-1187-6. Epub 2020 Feb 6.
6
Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking.系统遗传作图鉴定出 SLC39A7 是死亡受体运输的调节剂。
Cell Death Differ. 2019 Jun;26(6):1138-1155. doi: 10.1038/s41418-018-0192-6. Epub 2018 Sep 20.
7
Targeting the HTLV-I-Regulated BATF3/IRF4 Transcriptional Network in Adult T Cell Leukemia/Lymphoma.靶向 HTLV-I 调节的 BATF3/IRF4 转录网络治疗成人 T 细胞白血病/淋巴瘤。
Cancer Cell. 2018 Aug 13;34(2):286-297.e10. doi: 10.1016/j.ccell.2018.06.014. Epub 2018 Jul 26.
8
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.CD30下调、MMAE耐药和MDR1上调均与对维布妥昔单抗耐药相关。
Mol Cancer Ther. 2015 Jun;14(6):1376-84. doi: 10.1158/1535-7163.MCT-15-0036. Epub 2015 Apr 3.
9
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.单药 Brentuximab vedotin 治疗复发 T 细胞淋巴瘤的客观缓解。
Blood. 2014 May 15;123(20):3095-100. doi: 10.1182/blood-2013-12-542142. Epub 2014 Mar 20.
10
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔（SGN-35）治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.